logo

Neurocrine Biosciences Inc (NBIX)



Trade NBIX now with
  Date
  Headline
5/23/2022 8:32:23 AM Neurocrine Presents New INGREZZA Data On Tardive Dyskinesia Improvement And Stability Of Psychiatric Symptoms
5/4/2022 7:33:27 AM Neurocrine Biosciences Q1 Non-GAAP EPS $0.30 Vs $0.50 Prior Year
4/1/2022 8:32:08 AM Neurocrine Presents Phase3 Data For KINECT-HD Study Evaluating Valbenazine For Chorea Associated With Huntington Disease
3/24/2022 8:31:32 AM Neurocrine Biosciences To Present Data From Movement Disorder Portfolio At The American Academy Of Neurology 2022
2/11/2022 7:33:10 AM Neurocrine Biosciences Q4 Non-GAAP EPS Drops To $0.04 From $0.89 Last Year
11/30/2021 4:07:05 PM Neurocrine Biosciences Appoints Jude Onyia As Chief Scientific Officer
11/22/2021 8:02:41 AM Neurocrine And Sosei To Develop Muscarinic Receptor Agonists For Schizophrenia And Other Neuropsychiatric Disorders
11/2/2021 8:21:30 AM William Blair Is Increasing Neurocrine Biosciences Inc (NBIX) FY23 Rev. Estimate To 2.05 Billion From 1.98 Billion
11/2/2021 8:21:15 AM William Blair Is Increasing Neurocrine Biosciences Inc (NBIX) FY22 Rev. Estimate To 1.46 Billion From 1.40 Billion
11/2/2021 8:21:03 AM William Blair Is Increasing Neurocrine Biosciences Inc (NBIX) FY21 Rev. Estimate To 1.17 Billion From 1.15 Billion
11/2/2021 8:19:58 AM William Blair Is Lowering Neurocrine Biosciences Inc (NBIX) FY23 Estimate To 7.62 From 8.46
11/2/2021 8:19:43 AM William Blair Is Lowering Neurocrine Biosciences Inc (NBIX) FY22 Estimate To 3.25 From 3.74
11/2/2021 8:19:32 AM William Blair Is Lowering Neurocrine Biosciences Inc (NBIX) FY21 Estimate To 2.66 From 2.90
11/2/2021 8:18:45 AM William Blair Reiterates Neurocrine Biosciences Inc (NBIX) At Outperform